Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Email
Tweet this
Print
Michael Teufel, PhD (he/him/his)
Executive Director
Boehringer Ingelheim Pharmaceuticals, Inc.
Poster(s):
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Email Michael
